Analyst Says Maravai LifeSciences Not Immune From Macro Headwinds As Guidance Lags Consensus
Maravai LifeSciences Holdings Inc’s (NASDAQ:MRVI) Q1 revenue fell 68% Y/Y to $79 million, slightly below the consensus of $79.72 million. Nucleic Acid…